• Commercial revenue up 21% to $18.4M
• Net loss improved from $15.4M to $9.9M
• Operating expenses reduced by $2.6M

AVITA Medical reported financial results for the second quarter of 2025, with commercial revenue increasing 21% to $18.4 million compared to the same period in 2024. The company's net loss improved from $15.4 million in Q2 2024 to $9.9 million in Q2 2025, and total operating expenses decreased from $28.7 million to $26.1 million. The growth in commercial revenue was driven by deeper penetration within customer accounts, new accounts for trauma wounds, and new product launches. However, AVITA faced a significant headwind from a temporary gap in Medicare Administrative Contractor (MAC) payments to providers for the use of its flagship RECELL System, which led to a weakening in demand. The company has revised its full-year 2025 revenue guidance to a range of $76 million to $81 million, compared to the previous guidance of $100 million to $106 million. This new guidance reflects growth of approximately 19% to 27% over full-year 2024 revenue. AVITA expects to reach cash flow break-even in the second quarter of 2026 and GAAP profitability in the third quarter of 2026 as reimbursement pathways stabilize and adoption progresses.

Full-year 2025 revenue guidance revised to a range of $76 million to $81 million, compared to previous guidance of $100 million to $106 million. This new guidance reflects growth of approximately 19% to 27% over full-year 2024 revenue.

AVITA expects to reach cash flow break-even in the second quarter of 2026 and GAAP profitability in the third quarter of 2026 as reimbursement pathways stabilize and adoption progresses.